Hugel Inc (145020) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hugel Inc (145020) has a cash flow conversion efficiency ratio of 0.038x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩40.89 Billion ≈ $27.71 Million USD) by net assets (₩1.09 Trillion ≈ $737.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Hugel Inc stock valuation for the company's overall valuation and market capitalisation.
Hugel Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Hugel Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hugel Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hugel Inc ranked by their cash flow conversion efficiency. Explore 145020 cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ennoconn Corp
TW:6414
|
0.002x |
|
Guangdong No2 Hydropower Engineering Co Ltd
SHE:002060
|
0.053x |
|
Ashtrom Group Ltd
TA:ASHG
|
-0.090x |
|
Shenzhen Sinexcel Electric Co Ltd
SHE:300693
|
0.102x |
|
The Jammu & Kashmir Bank Limited
NSE:J&KBANK
|
-0.278x |
|
Ningbo ZhongDa Leader Intelligent Transmission Co Ltd
SHE:002896
|
0.021x |
|
NagaCorp Ltd
F:N9J
|
0.028x |
|
NCC AB (publ)
ST:NCC-B
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Hugel Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Hugel Inc from 2014 to 2025. View current stock price of Hugel Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩980.16 Billion ≈ $664.24 Million |
₩150.06 Billion ≈ $101.69 Million |
0.153x | -13.64% |
| 2024-12-31 | ₩840.81 Billion ≈ $569.81 Million |
₩149.05 Billion ≈ $101.01 Million |
0.177x | +17.42% |
| 2023-12-31 | ₩779.68 Billion ≈ $528.38 Million |
₩117.71 Billion ≈ $79.77 Million |
0.151x | +48.32% |
| 2022-12-31 | ₩792.11 Billion ≈ $536.80 Million |
₩80.63 Billion ≈ $54.64 Million |
0.102x | -7.96% |
| 2021-12-31 | ₩777.09 Billion ≈ $526.62 Million |
₩85.94 Billion ≈ $58.24 Million |
0.111x | +11.14% |
| 2020-12-31 | ₩746.67 Billion ≈ $506.01 Million |
₩74.30 Billion ≈ $50.35 Million |
0.100x | -9.59% |
| 2019-12-31 | ₩699.50 Billion ≈ $474.04 Million |
₩76.99 Billion ≈ $52.18 Million |
0.110x | +21.74% |
| 2018-12-31 | ₩727.72 Billion ≈ $493.17 Million |
₩65.80 Billion ≈ $44.59 Million |
0.090x | -2.01% |
| 2017-12-31 | ₩695.71 Billion ≈ $471.47 Million |
₩64.19 Billion ≈ $43.50 Million |
0.092x | -48.33% |
| 2016-12-31 | ₩252.80 Billion ≈ $171.32 Million |
₩45.14 Billion ≈ $30.59 Million |
0.179x | +87.79% |
| 2015-12-31 | ₩207.85 Billion ≈ $140.85 Million |
₩19.76 Billion ≈ $13.39 Million |
0.095x | -52.12% |
| 2014-12-31 | ₩53.21 Billion ≈ $36.06 Million |
₩10.57 Billion ≈ $7.16 Million |
0.199x | -- |
About Hugel Inc
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults… Read more